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Abstract
The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive
impairment (MCI), (2) delirium-onset, and (3) psychiatric-onset presentations. The purpose
of our review is to determine whether there is sufficient information yet available to justify
development of diagnostic criteria for each of these. Our goal is to achieve evidence-based
recommendations for the recognition of DLB at a predementia, symptomatic stage. We pro-
pose operationalized diagnostic criteria for probable and possible mild cognitive impairment
with Lewy bodies, which are intended for use in research settings pending validation for use in
clinical practice. They are compatible with current criteria for other prodromal neurodegen-
erative disorders including Alzheimer and Parkinson disease. Although there is still insufficient
evidence to propose formal criteria for delirium-onset and psychiatric-onset presentations of
DLB, we feel that it is important to characterize them, raising the index of diagnostic suspicion
and prioritizing them for further investigation.
Introduction
Dementia with Lewy bodies (DLB) accounts for 7·5% or more of all dementias in older
people.1 It is characterized by dementia together with varying combinations of the core clinical
features of parkinsonism, REM sleep behavior disorder (RBD), fluctuating cognition/alertness,
and visual hallucinations.2 There is a variable progression of α-synuclein aggregationmany years
before the full DLB syndrome develops,e1 which likely determines the pattern of early clinical
changes. Prodromal DLB refers to a predementia stage with signs or symptoms indicating that
DLB will subsequently develop and encompasses not only cognitive deficits but also a variable
mixture of noncognitive clinical features including motor symptoms and signs, sleep disorders,
autonomic dysfunction, and neuropsychiatric disturbance.3 Because these first clinical mani-
festations can occur 15 years or more before dementia onset, precise early diagnosis of DLB
presents particular challenges, individuals being extremely difficult to distinguish from those
with the first manifestations of Parkinson disease (PD) or multiple system atrophy (MSA),
which are also α-synuclein–related syndromes,4 or of other dementing disorders, particularly
Alzheimer disease (AD).
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Reliable identification of prodromal DLB would enable early
intervention while pathologic burden is circumscribed and
before clinical symptoms become debilitating. It would assist
clinicians to streamline care, anticipate treatment options
known to be effective in DLB,e2 and to avoid or minimize
iatrogenic adverse events with the goal of fewer office and
emergency department visits.e3 Importantly, early diagnosis
would help patients and families to plan and to implement
early nonpharmacologic interventions, (e.g., exercise and
behavioral strategies). It would also facilitate selection for
trials of targeted therapies as these become available.
Methods
We performed electronic searches of MEDLINE, PubMed,
and EMBASE databases using the combination of a number of
medical subject headings, Emtree subject headings, and free-
text terms (“dementia with Lewy bodies”, “Lewy body de-
mentia”, “Lewy body disease”, “prodromal”, “delirium”,
“psychosis”, “mild cognitive impairment”, “rapid eye move-
ment sleep behavior disorder” for clinical categories, and
“neuropsychological test”, “dopamine transporter imaging”,
“positron emission tomography”, “meta-iodobenzylguanidine
myocardial scintigraphy”, “nuclear magnetic resonance im-
aging”, “electroencephalography”, “cerebrospinal fluid”,
“rapid eye movement sleep without atonia” for biomarkers).
All relevant articles were retrieved, placing restrictions on
fields (free-text terms searched exclusively in the title or
abstract of the articles) and date (last 5 years). Except for
book chapters, all publication types (original articles,
reviews, editorials, and letters) were considered. Because the
focus of this review was on prodromal DLB, studies on the
broader, less specific category of Lewy body disease (which
comprises both DLB and PD) were also considered. We
then used Refworks to remove duplicates and share the
resulting 3570 records among the lead authors. Of all full-
text articles assessed for eligibility after the abstract screen-
ing phase, those eventually included either as listed or as
e-references were selected based on their relevance (data
available from Dryad, e-references, doi:10.5061/dryad.
1c59zw3rv). Seminal papers on the topic were included re-
gardless of publication date. The preliminary findings and
recommendations were presented for discussion and feed-
back at a session of the International Lewy Body Dementia
Conference in Las Vegas, NV, USA, in June 2019, following
which further revision and review took place.
How does prodromal DLB usually present?
One or more of the core clinical features characteristic of fully
developed DLB may develop before dementia and are usually
accompanied by mild cognitive complaints.5 Spontaneous
parkinsonism often develops within the predementia stage
but is not present in all patients.3,6 RBD is a parasomnia that
typically occurs years, and even decades, before the onset of
dementia or parkinsonism and may presage any of the
α-synucleinopathies.4,7,e4 In patients with mild cognitive def-
icits who later develop dementia, both parkinsonism and RBD
strongly predict a later transition to DLB rather than to AD or
other dementia types.6,8 Delirium can occur during the pre-
dementia stage of DLB9 as can fluctuations of cognition and
arousal3 that may give rise to a diagnosis of delirium. Visual
hallucinations (VHs) either spontaneous or provoked by ill-
ness or medication are more likely to occur compared with
normal controls or prodromal AD.10,11 There are also case
reports of delusions, hallucinations, depression, and anxiety as
presenting features of DLB.12 Based on such observations, 3
prototypic prodromal DLB syndromes have been proposed13
as (1) mild cognitive impairment (MCI), (2) delirium-onset,
or (3) psychiatric-onset.
MCI with Lewy bodies
The National Institute on Aging and Alzheimer’s Association
criteria for MCI14, e5 provide a standardized approach to di-
agnosis and form the basis for our proposed MCI with Lewy
body (MCI-LB) criteria. They require a cognitive complaint from
the patient or from an informant or clinician who knows them
and has observed a decline. Also required are deficits in one or
more cognitive domains that are greater than would be expected
from normal aging, do not represent lifelong patterns of lower
cognitive function, and are not associated with acute medical or
neurologic insults. Although people with MCI may be less effi-
cient or less capable at performing tasks they have performed
previously, their cognitive deficits should not be sufficient to
interfere with their typical daily functioning. In other words, there
should be an overall preservation of their prior level of in-
dependence with minimal interference in day-to-day functional
abilities, which, by definition, does not constitute a dementia.
Objective cognitive impairment is optimally based on stan-
dardized assessment with scores on neuropsychological
measures that are typically 1 to 1·5 SDs below the mean for
their age and education matched peers on culturally appro-
priate normative data (i.e., for the impaired domain(s), when
available). It is emphasized that these ranges are guidelines
Glossary
AD = Alzheimer disease; DAT = dopamine transporter; DLB = dementia with Lewy bodies; FTD = frontotemporal dementia;
MCI = mild cognitive impairment; MCI-LB = MCI with Lewy bodies; MIBG = meta-iodobenzylguanidine; MSA = multiple
system atrophy; NCD = neurocognitive disorder; PD = Parkinson disease; PSG = polysomnography; QEEEG = Quantitative
EEG; RBD = REM sleep behavior disorder; RSWA = REM sleep without atonia; VH = visual hallucination; VRH = ventilatory
response to hypercapnia.
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and not cutoff scores.14 Impairment on neuropsychological
tests may also be demonstrated by significant decline dem-
onstrated on serial testing or significant decline from esti-
mated premorbid abilities.e5 Cognitive impairment may
additionally be categorized as single or multiple domain, and
as amnestic or nonamnestic, which may help to classify po-
tential subgroups as they relate (1) to biomarkers and path-
ologic correlates, and (2) to differences in the rate of decline
and progression to dementia, each of which may be important
in the conduct of clinical trials. A further refinement to de-
scribe the cognitive profile of MCI-LB may be provided by
using the MDS level II criteria for PD-MCI.15,e6,e7
The cognitive presentation of MCI-LB
The cognitive pattern ofMCI-LB is similar toDLB and typically
includes disproportionate attention/executive and visual pro-
cessing deficits and relatively preserved memory and object
naming.16,e8,e9 Impairment on tasks of attention, processing
speed, and verbal fluency typically constitute the attention/
executive deficits, and tasks of visual discrimination, assembly,
and figure drawing typically constitute the visual perceptual and
spatial deficits.5,6,17–19
Diagnostic criteria for DLB emphasize that prominent or per-
sistent memory impairment may not necessarily occur in the
early stages,2 but patients and carers frequently offer memory
complaints as a presenting symptom.20Of 49 patients withMCI
who progressed to DLB, 27% had multidomain amnestic MCI,
but only 6% had single-domain amnestic MCI,3 similar to other
reports.19,21 When patients with MCI-LB have memory im-
pairment, attention and/or visual processing deficits also tend to
be present3 and may precede the memory difficulties. Patients
with RBD who later developed DLB had attention/executive
deficits up to 6 years before the diagnosis of dementia and
memory deficits up to 2 years before the diagnosis.22 The basis
for verbal memory impairment in DLB or MCI-LB may be
related to slowed processing speed and deficits in working
memory and retrieval that characterize the attention and exec-
utive deficits,e10 consistent with hippocampal preservation in
MCI-LB compared with MCI-AD.23,e11 However, impaired
memory in DLB may also be related to the extent of coexisting
AD-related pathology,e9 characterized by greater hippocampal
atrophy on imaging e12 and greater CA1 hippocampal subfield
pathology on autopsy..e13 Similar to other subtypes of MCI,
a proportion of patients may revert to being cognitively normal,
although they remain at a greater risk of the eventual de-
velopment of dementia.e14 Some instability of an MCI-LB di-
agnosis is to be expected given inherent fluctuating cognition,
worsening with neuroleptics or anticholinergics, or improve-
ment with levodopa-carbidopa or cholinesterase inhibitors.
In summary, the performance pattern of MCI-LB is best
characterized as single- or multidomain nonamnestic MCI, or
as multidomain amnestic MCI, whereas single-domain
amnestic MCI is more likely to represent MCI-AD. The
MCI-LB cognitive pattern is often seen in patients with 1 or
more core DLB features,5 although these may develop
later.3,18 Nonamnestic MCI seldom develops into AD but is
associated with a greater risk of transition to DLB10,21 with
a ten-fold risk compared with amnestic MCI.3 Because
a substantial subset of patients with DLB have coexisting AD-
related pathology that may influence their cognitive profile,
MCI-LB still should be considered an important part of the
differential diagnosis in amnestic subjects.
Operationalization of MCI-LB
The scheme suggested in table 1 for the identification ofMCI-LB
allows a diagnosis of either possible or probable MCI-LB based
on the number of qualifying clinical features or biomarkers. The
terms possible and probable refer to the likelihood of underlying
LB disease and not to the MCI syndrome. Structured diagnostic
instruments may assist identification of the core clinical features
of DLB that precede, coincide with, or follow the onset of cog-
nitive difficulties.24–26 Cognitive fluctuations may be of lesser
amplitude or frequency than in more severe disease. Passage and
sense of presence hallucinatory phenomena may precede the
development of recurrent, well-formed and detailed VH. Clinical
features supportive of DLBmay occur secondary to other causes
reducing their diagnostic specificity, but they can be useful
indicators of underlying LBdisease, particularly when they persist
over time or occur in combination.
Use of the possible MCI-LB category may raise diagnostic
suspicion prompting further clinical and biomarker in-
vestigation. Some possible MCI-LB combinations will likely
prove better predictors than others, for example, multidomain
nonamnestic MCI plus clinically well-defined RBD is antici-
pated to be more predictive of progression to DLB than
single-domain amnestic MCI plus a history of cognitive
fluctuation. The utility of different combinations of clinical
features and biomarkers remains to be established.
MCI-LB and PD-MCI
Uncertainty may occur in deciding how patients exhibiting
both MCI and parkinsonism are best categorized. PD-MCI
will usually be the most appropriate diagnosis when PD is
diagnosed before significant cognitive decline occurs. The
adoption of a 1-year rule similar to that used to separate DLB
and PD dementia may be helpful to distinguish someMCI-LB
and PD-MCI cases if the onset and order of mild symptoms of
parkinsonism and cognitive decline can be clearly established.
If not, an initial diagnosis of prodromal LB disease may be
preferable, recognizing that this will require revision as the full
clinical picture evolves. Individuals with poor global cognitive
test performance identified in community samples have been
reported to be at a greater risk of developing PD over sub-
sequent years,e15,e16 but poor cognitive test scores are not
equivalent to MCI, and this increased risk was no longer
statistically significant when individuals with subtle motor
signs at baseline were excluded.e15 There are data to suggest
that patients with MCI-LB may have greater cognitive im-
pairment than those with PD-MCI,27 but this is not easily
operationalized to differentiate individual subjects. The cog-
nitive deficits of PD-MCI can be heterogeneous,e17 with
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disproportionately affected attention/executive function,22
visuospatial skills,e18 and memory.28 Similar toMCI-LB, there
is evidence that nonamnestic MCI is more common than
amnestic MCI and that multidomain amnestic MCI is more
common than single-domain amnestic MCI.29
Biomarkers for prodromal DLB
Direct measures of α-synuclein pathology would offer de-
finitive diagnosis at an early stage; several are under de-
velopment, but none is yet validated or available for use
antemortem. Surrogate biomarkers of LB disease must
Table 1 Research criteria for the clinical diagnosis of probable and possible MCI-LB
Essential for a diagnosis of MCI-LB is MCI defined by the presence of each of the following:
Concern by the patient, informant, or clinician regarding cognitive decline.
Objective evidence of impairment in 1 or more cognitive domains. The cognitive impairment may include any domain, but is more likely to be associated
with attention-executive and/or visual processing deficits.
Preserved or minimally affected performance of previously attained independence in functional abilities, which do not meet the criteria for dementia.
Core clinical features
Fluctuating cognition with variations in attention and alertness.
Recurrent visual hallucinations.
RBD.
One or more spontaneous cardinal features of parkinsonism: these are bradykinesia (defined as slowness of movement and decrement in amplitude or
speed), rest tremor, or rigidity.
Proposed biomarkers
Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET.
Polysomnographic confirmation of REM sleep without atonia.
Reduced meta-iodobenzylguanidine (MIBG) uptake on myocardial scintigraphy.
Probable MCI-LB can be diagnosed if:
Two or more core clinical features of DLB are present, with or without the presence of a proposed biomarker, or
Only 1 core clinical feature is present, but with 1 or more proposed biomarkers.
Probable MCI-LB should not be diagnosed based on biomarkers alone.
Possible MCI-LB can be diagnosed if:
Only 1 core clinical feature of DLB is present, with no proposed biomarkers, or
One or more of the proposed biomarkers is present, but there are no core clinical features.
Supportive clinical features
Severe sensitivity to antipsychotic agents; postural instability; repeated falls; syncope or other transient episodes of unresponsiveness; prolonged or
recurrent delirium; autonomic dysfunction, e.g., constipation, orthostatic hypotension, urinary incontinence; hypersomnia; hyposmia; hallucinations in
other modalities including passage, and sense of presence phenomena; systematized delusions; apathy, anxiety, and depression.
Potential biomarkers of MCI-LB
Quantitative EEG showing slowing and dominant frequency variability.
Relative preservation of medial temporal lobe structures on structural imaging.
Insular thinning and gray matter volume loss on MRI.
Low occipital uptake on perfusion/metabolism scan.
MCI plus supportive clinical features or potential biomarkers are insufficient to diagnose MCI-LB but may raise suspicion of it and prompt biomarker
investigation and may add weight to an existing MCI-LB diagnosis.
MCI-LB is less likely in the presence of any other physical illness or brain disease including cerebrovascular disease, sufficient to account in part or in total for
the clinical picture, although these do not exclude anMCI-LB diagnosis andmay serve to indicatemixed ormultiple pathologies contributing to the clinical
presentation.
Abbreviations: DLB = dementia with Lewy bodies; MCI = mild cognitive impairment; MCI-LB = MCI with Lewy bodies.
These should be used in conjunction with the corresponding article text, which gives further information about core and supportive clinical features and the
use of biomarkers as they apply to MCI-LB.
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therefore be used, as is the case for the diagnosis of DLB
itself.2 We propose biomarkers for the diagnosis of prodromal
DLB, where there is either sufficient, good quality, published
evidence of adequate diagnostic specificity in prodromal DLB
or this can be reasonably extrapolated from fully developed
DLB or related disorders. We categorize biomarkers for which
only limited data are available as potential biomarkers, rec-
ognizing that such distinctions are likely to require revision as
new data become available.
Proposed biomarkers
Reduced dopamine transporter (DAT) uptake in basal
ganglia demonstrated by SPECT or PET
The utility of DAT imaging in discriminating DLB from AD
is already well established2 and its sensitivity in dis-
tinguishing MCI with LB (MCI-LB) fromMCI with AD was
54% and specificity 89%,30 whenMCI-LB was defined by the
presence of 1 core clinical feature of DLB in patients with
MCI. A higher sensitivity of 61% was achieved when 2 core
clinical symptoms were present.30 Reduced striatal DAT
uptake therefore seems suggestive of prodromal DLB in
a person with MCI, but normal striatal DAT uptake does not
exclude it.
Polysomnographic confirmation of REM sleep without
atonia
The association between RBD and synucleinopathy is highly
specific, (e.g., a multicenter autopsy study found that of 80
subjects with polysomnography [PSG]-confirmed RBD and
a coexisting neurodegenerative disorder, only 2 had a disease
unrelated to α-synuclein deposition).e4 These data imply that
a patient presenting with MCI and having PSG-confirmed
RBD, that is, a history of probable RBD plus clear docu-
mentation of REM sleep without atonia (RSWA) on PSG,
also has a high probability of an underlying prodromal syn-
ucleinopathy. Because around a quarter of patients with DLB
do not report symptoms of RBD and/or have normal REM
sleep atonia on PSG, a normal PSG does not exclude a pro-
dromal DLB diagnosis.31
Reduced meta-iodobenzylguanidine uptake on
myocardial scintigraphy
Reduced meta-iodobenzylguanidine (MIBG) uptake is an
indicative biomarker for DLB2 and has also been reported to
occur in a small series of patients with late-onset psychiatric
disorder and PSG-confirmed RBD,32 reinforcing its associa-
tion with underlying α-synucleinopathy. Of 2 patients with
amnestic MCI with low MIBG uptake, one developed DLB
after 2 years; the other had no clinical follow-up reported.e19
VHs and/or RBD were reported among 7 of 13 patients with
MCI with reduced MIBG uptake, the majority of whom also
had autonomic symptoms suggestive of LB disease, but they
were not followed to determine conversion to DLB.e20 De-
spite a paucity of longitudinal data,e21 there seems to be suf-
ficient evidence that abnormal MIBGmyocardial scintigraphy
in a patient with MCI supports a prodromal DLB diagnosis,
but further studies are required.
Potential biomarkers
These are biomarkers consistent with underlying LB disease,
which may help the diagnostic evaluation, but for which there
is still insufficient evidence of diagnostic sensitivity and
specificity in early disease. This will change as new evidence
emerges, at which point these, or other candidates, may be-
come considered as indicative of prodromal DLB.
Quantitative EEG showing slowing and dominant
frequency variability
EEG slowing has been reported as predictive of dementia in
both PDe22 and RBD,e23 posterior slow wave activity with
periodic fluctuations in the pre-alpha range being supportive
of DLB.2 Quantitative EEG (QEEG) methods show that
a dominant frequency <8 Hz and dominant frequency vari-
ability >1·5 Hz is typical of DLB, and in a 3-year, follow-up
study, 83% of subjects with MCI with this pattern at pre-
sentation converted to DLB. If these findings are replicated,
QEEG may represent a powerful predictor of progression
from MCI to DLB.33
Relative preservation of medial temporal lobe
structures on structural imaging
Absent or minimal medial temporal lobe atrophy is consistent
with DLB, but not sufficiently specific to differentiate it from
AD.2 Lewy body disease with RBD is characterized by pre-
served hippocampal volumes,34 and hippocampal preserva-
tion in patients with MCI supports progression to DLB
instead of AD dementia with a sensitivity of 85% and a spec-
ificity of 61%.23 Suboptimal specificity may be due to the
variability of hippocampal atrophy in AD35 and contribution
of other pathologic processes such as TAR DNA binding
protein 43 (TDP43).e24
Insular thinning and gray matter volume loss
Insular cortical thinning occurs in prodromal DLB relative to
healthy controls using MRI T1 sequences, with gray matter
atrophy predominantly affecting the anterior cingulum and
medial frontal structures. This contrasts with more extensive
loss of gray matter in the temporal, frontal, and parietal
regions of subjects with prodromal AD. Insular cortical
thinning may therefore differentiate patients with prodromal
DLB not only from healthy controls but also from their
prodromal AD counterparts.36 No group differences in insular
volumes are seen between DLB and AD at the dementia stage,
so longitudinal studies are required to determine its precise
value as an early diagnostic marker of DLB.37 Insula is also
involved early in frontotemporal dementia (FTD), being the
first cortical area to show atrophy in presymptomatic GRN,
MAPT, or C9ORF72 mutation carrierse25 and unlikely
therefore to be helpful in differentiating DLB from FTD.
Low occipital uptake on perfusion/metabolism scan
Occipital hypometabolism on FDG-PET is associated with
DLB,38 and together with relative preservation of posterior
cingulate metabolism (the cingulate island sign)e26 is a sup-
portive biomarker of DLB.2 How frequently the cingulate
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island sign is seen in prodromal DLB remains to be estab-
lished; significantly reduced posterior cingulate metabolism
may be a useful indication of the concurrence of additional
neurofibrillary tangle pathology.e27
Other biomarkers
There is currently no α-synuclein radioligand with sufficient
evidence supporting its utility for imaging DLB or any other
α-synucleinopathy, nor have any diagnostically applicable
biofluid, peripheral tissue, or genotypic biomarkers been
established.2 CSF measures cannot reliably discriminate be-
tween DLB and AD,39 although the measurement of CSF
α-synuclein aggregates using seeding aggregation assays such
as protein misfolding cyclic amplification and real-time
quaking-induced conversion is providing encouraging pre-
liminary results and may be extended to more accessible
biofluids including saliva, plasma, serum, or urine.e28 Com-
bining CSF markers may be useful; for example, addition of
CSF phospho-tau to α-synuclein significantly improved the
differential diagnosis between MCI-LB and MCI-AD in-
creasing sensitivity and specificity both > than 95%.e29 Other
direct or indirect biomarker candidates that may occur early
include identification of phosphorylated α-synuclein deposits
in peripheral nervous tissue from skin biopsy,40 gait ana-
lysis,e30 and abnormalities in color vision discrimination.41,42
The figure shows a framework for considering a wider range of
biomarkers in the setting of prodromal DLB determining the
extent to which AD-related pathology is contributing to the
dementia syndrome and influencing clinical trajectories in
these patients.43,44,e31,e32 Aβ42 declines earlier in AD than
DLB, whereas Aβ40 levels increase alone in AD. A low
Aβ42/Aβ40 ratio may therefore differentiate patients with
prodromal AD from patients with prodromal DLB better than
individual measures.43 There is also evidence showing dif-
ferent frequencies and topographies of abnormal uptake on
amyloid and tau PET imaging in DLB vs AD.45
Delirium-onset DLB
Cognitive fluctuations, or pronounced variations in alertness
and arousal, are a core feature of DLB, apparent as marked
fluctuations in cognitive ability or function, detectable by
observation or informant report, and measurable using sen-
sitive cognitive and electrophysiologic measures.e33 The oc-
currence of delirium (sometimes referred to as acute
confusional state) as an early presenting feature of DLB has
been described in numerous case reports and series,e34 in-
cluding in those with no apparent previous history of cogni-
tive impairment.46,e35 Whether this represents a greater
vulnerability to delirium in subjects with DLB, or the mis-
diagnosis of severe fluctuations with clouding of conscious-
ness as delirium, or a combination of both is unclear.
Recognition that DLB may first present as delirium is im-
portant because most guidelines for behavioral disturbances
in delirium recommend antipsychotics as first-line pharma-
cologic treatment. Delirium or marked fluctuations in con-
sciousness were reported by 43% of caregivers before DLB
diagnosis,47 and previous episodes of delirium were much
more frequent in patients with DLB compared with patients
with AD (25% vs 7%), with 1 in 4 of those with DLB having
repeated delirium.11 In the majority of these, potential pro-
voking causes were present. A similarly higher incidence of
delirium was found for subjects with DLB compared with
Figure Multimodal biomarkers for prodromal DLB
Reduced dopamine transporter uptake in basal gan-
glia demonstrated by SPECT or PET; PSG-confirmed
REM sleep without atonia and MIBG myocardial scin-
tigraphy are proposed as biomarkers of prodromal
DLB. Multimodality biomarkers are also important in
characterizing patients with prodromal DLB, in whom
the pathologic mechanisms of cognitive impairment
include both LB and AD pathologies and who may
have abnormalities associated with both. Medial
temporal lobe uptake on tau PET, medial temporal
lobe atrophy on MRI, and high levels of uptake on
amyloid PET and positive CSF biomarkers of AD-re-
lated pathology may characterize patients with pro-
dromal DLB with significant AD pathology. It is
expected that biomarker abnormalities detected in
the earliest stages will remain abnormal as disease
progresses, with additional biomarkers showing
changes later during the progression from pro-
dromal to dementia phase DLB. DLB = dementia with
Lewy bodies; MIBG = meta-iodobenzylguanidine.
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subjects with AD in the year before diagnosis (17·6 v 3·2/100
person-years),9 and admissions for delirium were more
common in those already diagnosed with DLB than for other
dementias. Prolonged delirium may also raise the index of
suspicion for DLB.e36 In an FDG-PET imaging study of
prolonged delirium, 32% of subjects were found to have
a DLB like pattern, a high proportion in regard both to the
known prevalence of the disease and to that of their matched
cognitively impaired control group (4%).e37
The similarities between the marked fluctuations in DLB and
disturbances of attention and consciousness in delirium have
been noted and reviewed,46 but there is as yet little un-
derstanding of a shared neurobiological basis. There have
been few pathologic studies, and although in an
epidemiologic-based autopsy cohort, there was no link be-
tween delirium and LB pathology at autopsy,e38 a significantly
increased risk of postoperative delirium in those with pe-
ripheral α-synuclein pathology has been described.48 Delirium
has been suggested to bemore common in those subjects with
DLB with later age at onset,e39 but further evidence is needed.
In summary (table 2), it is clear that DLB can present with
delirium, and in patients diagnosed with delirium, a careful
search for other DLB features should be made with a low
threshold for undertaking DLB biomarker examinations, es-
pecially in those with recurrent, unexplained, or prolonged
delirium. The extent to which delirium presentations of DLB
have the biomarker abnormalities associated with established
DLB or other prodromal DLB presentations is unclear,
although the PET imaging study cited above supports this,e37
as does a report of reduced DAT uptake in a patient with
acute, unexplained delirium.49 The link between delirium and
DLB is an important area for future research, to clarify the
relationship between the 2, and to establish which factors
associated with delirium should raise the index of suspicion
for underlying prodromal DLB.
Psychiatric-onset DLB
Early clinicopathologic studies suggested that DLB may
present as a primary psychiatric disorder,50,51 but subsequent
focus on the cognitive and motor aspects of DLB has limited
the documentation of such cases outside of a few
centers.12,32,52–54,e36 Late-onset major depressive disorder
and late-onset psychosis are the most frequently reported
presentations differing markedly from the construct of mild
behavioral impairmente40 and sometimes sufficiently severe to
require hospitalization. Symptoms include hallucinations in
visual and in other modalities and systematized delusions
including Capgras syndrome,55 apathy, anxiety, and de-
pression. Psychiatric-onset DLB cases are not easily differ-
entiated from non-LB late-onset psychosis cases on the basis
of primary psychiatric phenomenology or neuropsychological
profile alone.54 Psychomotor retardation such as slowed
speech, thinking, and body movements can resemble the
bradykinesia of parkinsonism. The occurrence of rest tremor
or rigidity is more helpful than bradykinesia to suspect pro-
dromal DLB in patients with depressive disorder,53 but
psychotropic-induced parkinsonism may complicate di-
agnosis. Atypical clinical features may prove valuable pointers
Table 2 Summary of key features of delirium-onset DLB
Patients with DLB are more susceptible to delirium than people with Alzheimer disease, and this delirium may occur as their presenting complaint before
dementia develops.
Such episodes may be provoked by multiple factors including surgery, infections/sepsis, fever, or other systemic illness, or secondary to use, or sudden
withdrawal of, alcohol or psychoactive drugs.
Prodromal DLB should be particularly suspected in patients
• in whom adequate provoking factors for the delirium are not found.
• with prolonged or recurrent delirium
• who later develop progressive cognitive decline or subsequent dementia
Core clinical features of DLB are likely to be of more limited diagnostic weight in a patient with delirium because
• cognitive fluctuation and clouding of consciousness can also occur in non-DLB delirium, i.e., are not diagnostically specific for DLB in this situation
• visual hallucinations may occur in non-DLB delirium, particularly drug-induced or provoked by alcohol abstinence
• motor parkinsonism present may be due to antipsychotic medications used to treat delirium
• the diagnostic significance of a history of RBD in a person with delirium is not yet established
Identification of delirium-onset DLB
• may be assisted by use of MCI-LB biomarkers, but further research evidence of this is required
• is important to inform the management plan including the avoidance or minimization of antipsychotic and anticholinergic agents
Abbreviations: DLB = dementia with Lewy bodies; MCI = mild cognitive impairment; MCI-LB = MCI with Lewy bodies; RBD = REM sleep behavior disorder.
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to underlying LB pathology, particularly the presence of re-
current VH12 when these occur before cognitive impairment
becomes evident. As with all α-synucleinopathies, RBD may
be a useful indicator, although a relationship between anti-
depressant usage and subsequent RBD onset is a potential
confounder.e41 Although the primary psychiatric manifes-
tations are often accompanied by mild cognitive deficits,54
cognitive evaluation and interpretation of performance can be
difficult when psychiatric symptoms are prominent. The fre-
quency of cognitive fluctuations in psychiatric-onset LB cases
has not been determined.
Initial reports suggest that 123I-MIBG scintigraphy may be
helpful in psychiatric-onset DLB.52,53,56 Eighteen of 35
patients with a first onset of major depressive disorder >50
years and with bradykinesia developed a clinical diagnosis of
DLB after 6 years of follow-up. All 18 had an abnormal ven-
tilatory response to hypercapnia (VRH), indicative of severe
autonomic dysfunction, whereas none of the 17 patients with
a normal VRH converted to DLB within the study period. For
the converters, the most common presentation was with
psychotic and melancholic features simultaneously. The fre-
quency of hypersensitivity to antipsychotics, antidepressants,
and antianxiety drugs was higher in converters than in non-
converters.53 Further studies need to confirm these findings
and to determine the value of other DLB biomarkers in
psychiatric-onset cases.32,52,56
In summary, it is not yet clear how to identify patients with
prominent late-onset psychiatric symptoms who may have
underlying LB disease and subsequently progress to DLB. It is
premature to try to construct formal criteria for psychiatric-
onset DLB, but clinicians in mental health and other settings
need to be aware that this possibility exists, not least because
of the risk of severe antipsychotic sensitivity reactions with
increased morbidity and mortality. The small available liter-
ature including reports such as those cited above does provide
some useful guidance, summarized in table 3, but requires
replication and further investigation.
Idiopathic REM sleep behavior disorder
RBD is characterized by abnormal dream enactment behavior
during REM sleep, accompanied by loss of muscle atonia during
REM sleep (REM sleep without atonia or RSWA) on PSG. For
the purpose of a prodromal DLB diagnosis, a clinical history of
RBD is obtained in the same way as for DLB,2 that is, a clear
complaint of dream enactment by a bedpartner or other witness,
with no evidence of sleep disorders that may mimic RBD on
clinical interview. Conditions known to mimic or masquerade as
RBD include non-REM parasomnias (sleep walking, sleep talk-
ing, or other behaviors that emerge fromnon-REM sleep stages),
obstructive sleep apnea, confusional arousals, or nocturnal seiz-
ures. In the absence of PSG, the risk of a false-positive clinical
diagnosis of RBD is reduced by using optimized sleep ques-
tionnaires, which can have sensitivity and specificity over 90%.e42
RBDmay be considered as idiopathic until it is associated with
another ongoing neurologic condition, the most frequent
being an α-synucleinopathy (PD, DLB, or MSA). In a recent
large study, 73.5% of patients with RBD converted to an overt
neurodegenerative syndrome after 12-year follow-up, 56.5%
developing parkinsonism, and 43.5% dementia as their first
Table 3 Summary of key features of psychiatric-onset DLB
Is characterized by predominant psychiatric symptoms that typically correspond to late-onset major depressive disorder or late-onset psychosis, which may
feature hallucinations in visual and in other modalities, and systematized delusions including Capgras syndrome
• may also present with apathy, anxiety, and depression
• may be sufficiently severe to require hospitalization
• the frequency of LB disease as a cause of late-onset psychiatric disorder is not known
When assessing for core clinical features of DLB in a patient with a primary psychiatric presentation:
• bradykinesia may be mimicked by psychomotor retardation, which is commonly seen in depressive disorders
• parkinsonism may be induced by antipsychotic medications used to treat psychiatric disorder
• RBD (and REM sleep without atonia) may be induced by antidepressant medications
• mild cognitive disturbance may be present but is not predominant and may fluctuate
• formal neuropsychological testing may be confounded by the psychiatric mental state
• the frequency and character of cognitive fluctuations is unknown
Identification of psychiatric-onset DLB
• may be assisted by use of MCI-LB biomarkers, but further research evidence of this is required
• is important to inform the management plan including the avoidance or minimization of antipsychotic and anticholinergic agents
Abbreviations: DLB = dementia with Lewy bodies; MCI = mild cognitive impairment.
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disease manifestation. Among many predictive markers
tested, only the cognitive variables differed at baseline be-
tween those converting to primary dementia vs parkinson-
ism.7 Other multicenter studies confirm that the only clinical
feature that predicts dementia vs parkinsonism first is neu-
ropsychological performance; those with RBD who exhibit
cognitive changes are more likely to evolve first into MCI or
DLB.22,e4 Thus, although RBD may be regarded an early
manifestation of α-synucleinopathy, it is not possible to clearly
distinguish whether an individual presenting with RBD will
develop dementia first, that is, evolve into a primary DLB
diagnosis, or parkinsonism first, that is., a primary PD/MSA
diagnosis. Any MCI subtype associated with PSG-confirmed
RBD is highly likely to represent underlying LB disease. Al-
though idiopathic RBD is a useful model to study the early
stages of LB disease progression, it is not necessarily repre-
sentative of the whole spectrum of patients with PD and DLB,
a significant minority of whom do not have RBD.42
Autonomic dysfunction/anosmia and other
nonspecific prodromal LB disease symptoms
Patients with DLB frequently report a history of autonomic
dysfunction at first clinic attendance, with 25%–50% com-
plaining of one of more among constipation, orthostatic diz-
ziness, urinary incontinence, erectile dysfunction, increased
sweating, or increased saliva.56,57 In a cohort of patients with
pure autonomic failure, 34% converted to an overt α-synu-
cleinopathy over 6 years of follow-up; this was to DLB (52%),
PD (24%), orMSA (24%).58 However, because there are many
other causes for autonomic dysfunction in older people, these
symptoms, either alone or in combination, have low positive
predictive value.59 The situation is similar for hyposmia, which
also frequently occurs early in prodromal DLB and PD,42 but
which can have many other causes in this age group.
Conclusions and future direction
Diagnosis of DLB at the dementia stage depends on identifying
fully expressed core clinical features, which may be mild or
absent at the prodromal stage when biomarker evidence may
also be weaker and may even differ from that found at the
dementia stage. Several new biomarker candidates, direct and
indirect, are in development, and we will continue to review
these to update our recommendations as soon as sufficient
evidence accumulates. We recognize that the clinical pheno-
type of neurodegenerative disorders reflects interaction be-
tween several rather than a single brain pathology, and it is
therefore likely that multiple biomarkers of individual pathol-
ogies (e.g., α-synuclein, β-amyloid, and tau), or of disease sur-
rogates (e.g., metabolic imaging/EEG), will be required.
Although we have described the 3 prodromal DLB syndromes
separately, they are unlikely to be mutually exclusive, and
there may be substantial overlap. We propose operationalized
criteria only for MCI-LB because the evidence base from our
systematic review, albeit relatively limited, is sufficient to
support recommendations that are immediately applicable
and testable. Our recommendations should be used alongside
guidance about the prodromal manifestations of PD,15,59
MSA,60 and AD14 with which there is overlap. Notwith-
standing the potential benefits of early diagnosis, we are also
mindful of the importance of avoiding incorrect (false-
positive) diagnosis of prodromal DLB and the potential
negative consequences this could have for an individual. We
suggest that the predictive validity of different categories and
combinations of our proposed criteria should be clarified by
prospective studies before they are adopted for widespread
clinical use and that they will enable standardization for in-
clusion in research studies and clinical trials.
Some published guidance about the early clinical diagnosis of
DLB does already exist. DSM5 recommends a diagnosis of
mild neurocognitive disorder (NCD) with LB “for individuals
who present with the core or suggestive features at a stage
when cognitive or functional impairments are not of sufficient
severity to fulfill criteria for major NCD”.e43 This is based,
however, on the 2005 version of DLB guidelines and requires
updating. ICD-11 takes a similar approach toward diagnosing
mild NCD at a syndromic level and lists both Lewy body
disease and PD as possible causes.e44
The diagnostic position for other prodromal manifestations of
DLB, that is, delirium-onset and psychiatric-onset, is less clear
than for MCI. Operationalization of specific criteria for these
syndromes is not yet justified, and the reliable differentiation
of the minority of delirious and psychiatrically ill patients who
have underlying LB pathology, from the majority who do not,
will probably only be achieved when routinely applicable
biomarkers are developed. LB disease is seldom, if ever, cur-
rently considered as part of the differential diagnosis of de-
lirium or late-onset psychiatric disorder, and we hope that the
information we provide in the text and accompanying boxes
will raise clinicians’ awareness of that possibility.
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